Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
Lori M B LaffelW V TamborlaneA YverG SimonsJ WuV NockD HobsonK S HughanS KaspersJ MarquardPublished in: Diabetic medicine : a journal of the British Diabetic Association (2018)
After a single oral dose of empagliflozin, adults and young people with Type 2 diabetes had similar exposure-response relationships after adjusting for significant covariates. These data support testing 10-mg and/or 25-mg doses of empagliflozin in an upcoming paediatric phase III Type 2 diabetes trial. (ClinicalTrials.gov registration no.: NCT02121483).
Keyphrases
- phase iii
- open label
- type diabetes
- clinical trial
- phase ii
- double blind
- placebo controlled
- intensive care unit
- emergency department
- cardiovascular disease
- electronic health record
- study protocol
- big data
- glycemic control
- randomized controlled trial
- insulin resistance
- metabolic syndrome
- adipose tissue
- artificial intelligence